Evidence map›Paper›PMID 34467675›Full record

ArticleNeuropsychopharmacology reports2021

Oral corticosteroid dosage and clinical presentation of psychiatric conditions after steroid use: A consultation-liaison psychiatry service's experience.

Yuko Yagi, Yusuke Takahashi, Yu Ogata, Hayato Yamana, Yousuke Kumakura, Kayo Ichihashi, Kiyoto Kasai, Shinsuke Kondo

Open access · goldAbstract read
In one paragraph

Article in Neuropsychopharmacology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Asthma and corticosteroids "Frontiers in allergy · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Yuko YagiDepartment of Neuropsychiatry, The University of Tokyo Hospital, Bunkyo-ku, Japan.ORCID 0000-0001-6024-0661
Yusuke TakahashiDepartment of Neuropsychiatry, The University of Tokyo Hospital, Bunkyo-ku, Japan.
Yu OgataDepartment of Neuropsychiatry, The University of Tokyo Hospital, Bunkyo-ku, Japan.ORCID 0000-0003-0803-0514
Hayato YamanaDepartment of Neuropsychiatry, The University of Tokyo Hospital, Bunkyo-ku, Japan.
Yousuke KumakuraDepartment of Neuropsychiatry, The University of Tokyo Hospital, Bunkyo-ku, Japan.
Kayo IchihashiDepartment of Neuropsychiatry, The University of Tokyo Hospital, Bunkyo-ku, Japan.
Kiyoto KasaiDepartment of Neuropsychiatry, The University of Tokyo Hospital, Bunkyo-ku, Japan.
Shinsuke KondoDepartment of Neuropsychiatry, The University of Tokyo Hospital, Bunkyo-ku, Japan.ORCID 0000-0001-5849-3889
University of Tokyo Hospital · JPBunkyo University · JPJapanese Red Cross Medical Center · JPSt. Luke's International Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimPsychiatric disturbances are the major adverse effects of corticosteroids. There are no consistent conclusions regarding changes in steroid dosage and the incidence of psychiatric conditions, due in part to the lack of consistent evaluation criteria. The purpose of this research was to determine the incidence and dose-dependency of psychiatric conditions as assessed by trained psychiatrists.

methodsA retrospective chart review was conducted at a university hospital in Japan. We identified inpatients receiving oral prednisolone treatment, who were referred to the consultation-liaison psychiatry team from April 2015 to March 2018. Patients were divided into high-dose (≥0.5 mg/kg/day) and low-dose (<0.5 mg/kg/day) groups. We investigated the associations between steroid dosage and incidence of psychiatric conditions.

resultsA total of 93 patients (35 in the high-dose group, 58 in the low-dose group) were included. Various psychiatric conditions, such as insomnia, delirium, depression, and psychosis, occurred during steroid therapy. The most common condition was insomnia (72%). We observed no significant differences in the patient background characteristics and the incidence of most psychiatric conditions between the high-dose and low-dose groups. However, there were more patients with delirium in the low-dose group than in the high-dose group.

conclusionsBased on the accurate assessment of psychiatric conditions by psychiatrists, our analysis suggests that, among inpatients referred to a consultation-liaison psychiatry team, the incidence of psychiatric conditions, with the exception of delirium, is independent of the dose of oral prednisolone.

Indexed as

PsychiatryAdrenal Cortex HormonesHumansInpatientsReferral and ConsultationRetrospective StudiesAdrenal Cortex Hormonesconsultation-liaison psychiatrycorticosteroiddeliriumsteroid-induced psychiatric disordersteroid psychosis

Identifiers

PMID34467675
PMCPMC8698699
OpenAlexW3197744040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.